Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug to treat erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are main desired properties. Dicot's main strategy is to develop LIB-01 in-house up to and including clinical phase 2a study, and then in partnership with major pharmaceutical companies to finance and further develop LIB-01 into a registered drug for the world market.